Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)

By  

Oncology, Vol. 89, Iss. 2, 2015-03 ,pp. : 70-78

Karger

Access to resources Recommend Favorite

BRCA status in epithelial ovarian cancer: implications for management and future clinical trial design

By Konstantinopoulos Panagiotis A   Matulonis Ursula A  

Clinical Investigation, Vol. 3, Iss. 8, 2013-08 ,pp. : 777-790

Future Science

Access to resources Recommend Favorite

Impact of clinical trial design and execution-related factors on incidence of thromboembolic events in cancer patients: a systematic review and meta-analysis

By Reynolds Matthew W.   Shibata Atsuko   Zhao Sean   Jones Natalie   Fahrbach Kyle   Goodnough Lawrence Tim  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 497-505

Informa Healthcare

Access to resources Recommend Favorite

Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting

By Kalinsky Kevin   Hershman Dawn L  

Journal of Comparative Effectiveness Research, Vol. 2, Iss. 4, 2013-07 ,pp. : 393-403

Future Medicine

Access to resources Recommend Favorite

Clinical Studies with Anticoagulants to Improve Survival in Cancer Patients

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 36, Iss. 3-4, 2009-01 ,pp. : 204-211

Karger

Access to resources Recommend Favorite